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This article aims to highlight the positions of the Food and Drug Administration and the European Medicines
Agency regarding use and marketing of hydroxyethyl starch (HES) products, and how these have changed over
recent years. In 2013, warnings from both agencies advised against use of HES in critically ill patients, including
patients with sepsis, when several large randomized controlled trials on volume resuscitation in critical illness failed
to observe clinically beneficial effects of HES. In areas such as patient monitoring and requirements for further
clinical trials, the FDA and EMA are very much in agreement in their recommendations. However, EMA guidance is
generally more restrictive on HES usage compared to that from the FDA. Differences in data presented to
regulatory authorities, bias in study results and inherent weakness of meta-analyses used for drug surveillance
purposes, plus different risk-management approaches used by the two regulatory authorities, likely contribute to
different outcomes in their regulations concerning use of HES.
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The Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) are two of the most
influential drug regulatory authorities in the world, and
are responsible for reviewing and regulating biomedical
products and supervising clinical trials, marketing
approvals, and risk-management processes. The FDA su-
pervises these processes in the United States of America,
whereas in the European Union this is overseen in a
coalition of federal organisations that includes the EMA,
the European Commission, and the national authorities
of the member states. The EMA and FDA have different
evaluation processes; therefore, despite the submission
of identical clinical data supporting the same drug,
the two bodies can come to different evaluations and
conclusions [1].* Correspondence: christian.wiedermann@claudiana.bz.it
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This document aims to highlight the summary positions
of the FDA and EMA regarding use and marketing of
hydroxyethyl starch (HES) products, and how these have
changed over recent years. HES is an artificial colloid
used worldwide for volume resuscitation [2]. Regulatory
decisions regarding HES are controversial [3], partly due
to use of meta-analyses for safety evaluations, which is
known to be problematic [4].Method
Source information for this summary was retrieved from
the FDA and EMA websites [5, 6] using the following
general search terms: ‘HES’, ‘hydroxyethyl starch’, ‘tetra-
starch’, and ‘hetastarch’, plus specific product names:
Hespan, Hextend, Voluven and Tetraspan. An overview
of events in HES usage between 2010 to present day is
shown in Table 1. Changes in regards to labelling and rec-
ommendations issued by the FDA and EMA, including
dosage, indications, contraindications, adverse effects,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Timeline of HES regulatory key events between 2010 to current practice
Safety concern 2010 – Publication of Cochrane review of HES effects on kidney function. Increased risk in septic shock patients with
10% HES 200/0.5 or 6% HES 200/0.6 [28] (Not based on US studies, i.e. HES formulations studied are different from
those FDA approved.
2012 – Publication of CRYSTMAS (May 2012), 6S (Jul 2012), & CHEST (Nov 2012) trials (plus others) [12–14]
Timeline FDA EMA
Before 2010 1972 – Approval of HESPAN (6% HES 450/0.7)
1991 – Approval of Hetastarch (6% HES 450/0.7)
1999 – Approval of Hextend (6% HES 450/0.7)
2007 – Approval of Voluven (6% HES 130/0.4)
HES-containing medicinal products
(>60 available throughout Europe)
in use for decades [29]
2012 May Change to Voluven labelling to include increased frequency
and duration of renal replacement therapy among Voluven
patients and info on paediatric dosage (in response to
CRYSTMAS study) [30]
2012 Sept Expert workshop set up by FDA to discuss HES products
in light of recent data [27]
2012 Nov Article 31 referral received following concerns over safety of
HES products – review conducted by PRAC [31]
2013 Jun PRAC recommends suspending marketing authorisations (MA)
for all HES products and their use in all patient populations [32]
2013 Jun MA holders appeal against decision [32]
2013 Oct PRAC revises recommendation upon completion of review. HES
solutions may continue to be used in restricted patient
population and additional studies should be conducted [16]
2013 Oct CMDh endorses PRAC recommendations, decision sent to
European Commission [16]
2013 Nov Addition of black box warning to product information regarding
increased mortality and kidney injury in critically ill patients [28]
2013 Nov Additional warning about excessive bleeding needed in the
Warnings and Precautions Section of the package insert -
considered a class effect [27]
2013 Nov Voluven label change: “Severe liver disease” added to
contraindication due to data from CHEST trial [30]
2013 Dec EU-wide decision to allow HES product use in restricted
patient population [16]
2014 Mar Revised product information formally issued across entire EU [16]
2014 Sept Additional precaution added to paediatric use section
(Voluven) [33]
2014 Oct PASS protocol rejected by PRAC due to issues with the
study design [34]
2015 Mar PASS protocol approved by PRAC [35]
2015 Jul Another PASS protocol rejected by PRAC due to inadequate
sample size [36]
Benefits of HES products in approved indications remain
favourable. No changes to labelling or MA [36]
2015 Oct PRAC issued advice and recommendations (requested by EU
member states) regarding submitted PASS protocols [37]
2015 Nov PASS protocol approved by PRAC [38]
Current Two post-marketing commitments fulfilled
(Voluven) [13, 39, 40]
Routine surveillance using FAERS.
HES products listed under ‘Medicines under additional monitoring’
by EMA since 2013 as further PASS required and all data reviewed
periodically (PSUR)
Post-authorisation commitment to perform additional studies in
patients with trauma and in elective surgery [16]
MAH (Serum Werke Bernburg) HES products licence suspension
for 1 year from Sept 2015 to Sept 2016 [41]
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Table 1 Timeline of HES regulatory key events between 2010 to current practice (Continued)
Further, PASS protocol submitted to be discussed at Sept
2016 meeting [42]
Future Use of HES in perioperative settings and the potential dose
dependency of HES administration in relation to acute kidney
injury to be assessed [36]
Abbreviations: CMDh Coordination Group for Mutual recognition and decentralised Procedures – human, FAERS FDA Adverse Event Reporting System, MAH
Marketing Authorisation Holder, PASS Post-Authorisation Safety Study, PRAC Pharmacovigilance Risk Assessment Committee, PSUR Periodic Safety Update Report
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marized in Table 2.
FDA and EMA policy changes
A key event in the regulation of HES occurred in 2013,
when both agencies advised against its use in critically ill
patients, including patients with sepsis. Several large
randomized controlled trials (RCTs) on volume resusci-
tation in critical illness with low risk of bias failed to ob-
serve clinically beneficial effects of HES (for a review,
see [7]) and confirmed previous doubts regarding the
safety profile of tetrastarches [8]. This included an asso-
ciation between colloid exposure and morbidity, includ-
ing acute renal failure in various clinical settings [9].
Moreover, randomized trials and meta-analyses have
demonstrated that HES increases the need of renal re-
placement therapy, including in surgical patients [10],
with tissue storage of HES cited as a likely mechanism
of toxicity [11].
Publication of these and other pivotal studies led the
FDA and EMA to instigate a review of HES product
usage. In September 2012 the FDA convened a work-
shop with experts from academia, industry, and other
relevant stakeholder to discuss the risks and benefits of
HES products. Similarly, in November 2012, a review
was opened by the EMA at the request of the German
medicines agency, following concerns relating to the
safety of HES products. During these reviews both agen-
cies reviewed the data from RCTs, meta-analyses and
observational studies, with a particular emphasis on 6S,
CRYSTMAS (FDA only), CHEST and VISEP studies
(EMA only) [12–15].
The outcome of these reviews led to several key regu-
latory decisions by the FDA and EMA, as outlined in
Table 1. These included the FDA issuing new safety in-
formation as a black box warning (Nov 2013), and the
suspension and subsequent limitations of marketing and
use of HES products in restricted patient populations by
the EMA (June 2013; Oct 2013) [16]. In addition, the
FDA and EMA also updated their guidance on dosage,
indication, contraindication, adverse effects, warning,
precautions and patient monitoring in relation to the
use of HES products (Table 2). Generally, the EMA
restricts use of HES to a greater extent than the FDA. In
areas such as patient monitoring and the requirementfor further HES clinical trials, the FDA and EMA are
very much in agreement; however, differences in con-
traindications are evident, which suggests that risk-
management approaches used by the two regulatory
authorities differ. The EMA oversees more than 60
HES products currently on the market within the EU
and is required to work with each member states’
regulatory authority; this added complexity can inher-
ently result in more restrictive measures when com-
pared to the FDA. For example, the FDA and EMA
definitions of conditions can vary, such as for hypo-
volemia where the FDA definition is broad, whereas
the EMA specify different types.
Data quality
Unpublished and misreported studies make it difficult for
regulatory bodies to determine the true value of a treat-
ment [17]. The CHEST trial [14], a large-scale, rando-
mised controlled trial to evaluate the safety and efficacy of
6% HES in ICU patients, erroneously misreported safety
data on pruritus induced by HES vs. saline, which was
considered serious enough by the editors of the NEJM
that a corrigendum was published [18]. This may be
significant because the true value of HES remains con-
troversial [7, 19] and pruritus is among its known side
effects [11]. Fresenius Kabi, a major manufacturer of
tetrastarch and other HES products, as well as a funder
of the CHEST trial, questioned the trial’s reporting in
the NEJM. The British Medical Journal finally pub-
lished on the dispute between Fresenius Kabi and the
CHEST investigators [20, 21] as part of the open data
campaign [22].
Regulatory authorities’ risk-management approaches
include thorough analyses of results from RCTs. Regard-
ing regulatory summaries for HES, selective outcome
reporting has previously been identified in publications
of the CRYSTMAS and FIRST trials [23]. For example,
in the CRYSTMAS trial, Fresenius Kabi was involved in
the study design, analysis and preparation of the report
[23]. Also, a meta-analysis of RCTs on use of HES for
volume resuscitation in cardiac surgery concluded that,
as compared to other volume resuscitation solutions,
HES had no adverse effects on blood loss, transfusion
requirements, and length of hospital stay [24]. The pub-
lication’s addendum states that Fresenius Kabi presented




Administer 500 to 1000 mL.
Doses of more than 1500 mL/day for the typical
70 kg patient (approx. 20 mL/kg) are usually not
required although doses of isotonic solutions
containing 6% hetastarch up to 1500 mL have
been used during major surgery. Volumes in
excess of 1500 mL/day have been used where
severe blood loss has occurred.
Newborns and children
Adequate, well controlled clinical trials to
establish the safety and effectiveness of






Administer up to 30 mL/kg/day. This dose
is equivalent to 2100 mL for a 70 kg patient.
Give initial 10–20 mL by slow infusion and
monitor for adverse effects.
Newborns and children
Limited data on the use of 130/0.4 HES in
children is available - if used individualised
dose taking into account disease and
haemodynamic status should be employed.
6% Tetrastarches
Identical to FDA
No change to adult dosage guidelines in 2012
Extra information to Voluven label in 2012
<2 years: Mean dose of 16 mL/kg IV
2–12 years: Mean dose of 36 mL/kg IV
No change to adult dosage guidelines in 2012
Extra information to Voluven label in 2012
<2 years: Mean dose of 16 mL/kg IV
2–12 years: Mean dose of 36 mL/kg IV
Indications Hetastarches indicated for treatment of hypovolaemia
when plasma volume expansion is desired.
It is not a substitute for blood or plasma.
Treatment of imminent or manifest hypovolaemia
and shock.
No changes to indication text in 2012 Change to indication text in 2013
In case of hypovolaemia a crystalloid solution
should first be given.
HES is indicated for the treatment of hypovolaemia
if patient does not respond to crystalloid solution.
Contra-indications Renal failure (with oliguria or anuria)
Hypersensitivity
Congestive cardiac failure
Treatment of lactic acidosis
Patients on dialysis
Clinical conditions with volume overload
Renal failure (with oliguria or anuria)
Hypersensitivity
Congestive cardiac failure
Hyperhydration states including pulmonary edema
Intracranial bleeding
Severely impaired hepatic function
Hyperkalaemia
Severe hypernatremia or hyperchloremia
Clinical conditions with volume overload
Additional contraindications in 2013
Critically ill adult patients, including patients with
sepsis, and those admitted to the ICU
Pre-existing renal function
Severe liver disease
Patients with pre-existing coagulation and bleeding disorders
Additional contraindications in 2013
Critically ill patients, including patients with sepsis
Burn injuries
Renal impairment or renal replacement therapy patients
Severe coagulopathy
Organ transplant patients
Adverse Effects Additions to adverse effects in 2013
Increased mortality in severe sepsis and other conditions
requiring ICU admission
Increased need for RRT in severe sepsis and other conditions
requiring ICU admission





Black box warning added to label in 2013
Avoid use in patients with pre-existing renal dysfunction
Discontinue use of HES at the first sign of renal injury
Avoid fluid overload; adjust dosage with cardiac or renal
dysfunction
Restriction on patient population added to label in 2013
Only use HES during the first 24 hours of fluid resuscitation
treatment
Trauma and surgery: carefully weigh the expected
benefit of treatment against the uncertainty of the
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Table 2 Changes to guidance on HES products from the FDA and EMA between 2012 and 2016 (Continued)
In cases of severe dehydration, a crystalloid solution
should be given first
long term safety
of treatment. Consider other available treatment options
Stop HES treatment at the first sign of impaired blood
clotting or renal injury
Not recommended for patients undergoing open heart surgery
Patient Monitoring Monitor fluid balance, serum electrolytes, renal and
hepatic function, acid–base balance, and coagulation
parameters during prolonged parenteral therapy or
when warranted
Because of the risk of allergic (anaphylactoid) reactions, the
patient should be monitored closely and the infusion instituted
at a low rate
Monitor fluid balance, serum electrolytes, renal and hepatic
function. Particular caution in patients with renal impairment
and elderly patients
Elevated serum amylase levels may be observed and can interfere
with the diagnosis of pancreatitis
Additions to guidance in 2013
Monitor renal function in hospitalized patients for at least
90 days as use of renal replacement therapy has been
reported up to 90 days after administration of HES products
Monitor the coagulation status of patients undergoing open
heart surgery in association with cardiopulmonary bypass as
excess bleeding has been reported with HES solutions in this
population. Discontinue use of HES at the first sign of
coagulopathy
Monitor liver function in patients receiving HES products
Additions to guidance in 2013
Monitor kidney function in patients receiving HES for at least
90 days and stop HES treatment at the first sign of renal injury
Blood coagulation parameters should be monitored carefully in
case of repeated administration
HES solutions should be used at the lowest effective dose for
the shortest period of time
Treatment should be guided by continuous haemodynamic
monitoring so that the infusion is stopped as soon as appropriate
haemodynamic goals have been achieved
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tions arising under Article 31 and to fulfil Article 107i of
the process regarding the perioperative use of HES. In
addition, the authors state that statistical analysis had
been conducted by MARCO and had been provided by
Fresenius Kabi [24]. The conclusion of lower blood loss
with tetrastarch than with pentastarch from this study is
attributable to publication bias, since an unpublished
trial with higher blood loss and more frequent reopera-
tion for bleeding after tetrastarch was omitted from this
meta-analysis [24]. Conversely, it was included in a
meta-analysis from 2012 [24] on the same indication,
which found that HES products increase postoperative
blood loss, need for blood product transfusions, and
need for re-operations [25, 26]. Findings from the 2012
meta-analysis contributed to the FDA’s decision to issue
a security warning because of excessive bleeding as a
class effect of all HES solutions (boxed warning for the
use of HES [27]). Incidentally, the tetrastarch manufac-
turer who commissioned the 2014 meta-analysis [21]
had previously submitted the unpublished trial (study
No. HS-13-24-EN in the 2012 meta-analysis [25]) to the
FDA in a New Drug Application. This observation sup-
ports the hypothesis that diverging summaries of the
FDA versus the EMA may be based on different type
and quality of data that drug manufacturers present to
regulatory authorities.
Conclusions
A significant change to guidelines regarding use of HES
for volume replacement was introduced in 2013 by both
the FDA and EMA, warning of increased risk of death
and renal injury and advising against use of HES incritically ill patients, including patients with sepsis. Both
agencies have adopted a similar stance regarding HES
usage, but the EMA restricts use to a greater extent. For
example, the EMA warning also includes burn injuries
as a contraindication, and includes additional advice
stating crystalloids should be the first-line treatment;
HES should be used only where crystalloids alone are in-
sufficient, and only then for short periods of time.
In areas such as patient monitoring and the require-
ment for further HES clinical trials, guidelines from the
FDA and EMA are generally in agreement. Slight varia-
tions exist regarding dosage recommendations, but the
majority of HES products used in the USA are hetas-
tarches, whereas in Europe tetrastarches appear to be
predominant.
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